Rocklatan for Glaucoma

Overseen By Clinical Research Manager

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: Center for Sight Las Vegas

Must not be taking: Steroids

Disqualifiers: Severe glaucoma, Retinal diseases, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 4-5 weeks

68 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.

Who Is on the Research Team?

Medical Director, Medical Doctor

Principal Investigator

Center For Sight

Are You a Good Fit for This Trial?

This trial is for individuals who have undergone Hydrus Microstent surgery to treat glaucoma and are looking for additional ways to lower their intraocular pressure. Specific eligibility criteria details were not provided.

Inclusion Criteria

Unmedicated or washed out IOP range between 16-26 mmHg

I have mild to moderate Open Angle Glaucoma.

I had cataract surgery with a Hydrus microstent over 3 months ago but less than 2 years ago.

Exclusion Criteria

Pregnant, breastfeeding or planning to become pregnant during the study

I have had or currently have an eye infection or inflammation.

I had laser eye surgery within the last 18 months.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Rocklatan or placebo comparator for intraocular pressure reduction

4-5 weeks

Regular visits for intraocular pressure measurements

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Rocklatan

Trial Overview The study aims to see if adding Rocklatan (a combination of netarsudil and latanoprost) after the Hydrus Microstent surgery can further reduce eye pressure in glaucoma patients, compared with a standard treatment using Systane.

How Is the Trial Designed?

Group I: FDA Approved Rocklatan (netarsudil 0.02% and latanoprost 0.005%) Active Control 1 Intervention

FDA approved Rocklatan (netarsudil 0.02% and latanoprost 0.005%) is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Group II: Placebo Comparator Systane Artificial Tears Placebo Group 1 Intervention

Comparator arm is Systane artificial tears

Who Is Running the Clinical Trial?

Center for Sight Las Vegas

Lead Sponsor